276 active
/
1320 total (since 2015)
58
Phase 1 Active
364 total
76
Phase 2 Active
291 total
80
Phase 3 Active
373 total
75
Phase 4 Active
342 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Eli Lilly 22 83 5
Novo Nordisk 14 135 3
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 7 3 0
Fujian Shengdi Pharmaceutical Co., Ltd. 5 8 0
Gan & Lee Pharmaceuticals. 5 0 0
Jiangsu HengRui Medicine Co., Ltd. 4 11 0
Shandong Suncadia Medicine Co., Ltd. 4 6 0
Gan and Lee Pharmaceuticals, USA 4 6 0
Daewoong Pharmaceutical Co. LTD. 3 5 0
BrightGene Bio-Medical Technology Co., Ltd. 3 2 0
Amgen 3 2 0
Roche 3 1 0
Guangdong Raynovent Biotech Co., Ltd 3 0 0
Sanofi 2 45 9
Merck 2 12 0
NCT07448974 NOT YET RECRUITING
Vitamin D and Type 2 Diabetes - Treat-To-Target
Tufts Medical Center n=100
NCT07064473 RECRUITING
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Boehringer Ingelheim n=11,800
NCT06739122 RECRUITING
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company n=55
NCT07428746 NOT YET RECRUITING
Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
Emory University n=20
NCT06066528 ACTIVE NOT RECRUITING
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
Boehringer Ingelheim n=755
NCT07417306 NOT YET RECRUITING
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=912
NCT06184568 ACTIVE NOT RECRUITING
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Innovent Biologics (Suzhou) Co. Ltd. n=349
NCT07351058 NOT YET RECRUITING
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
Hoffmann-La Roche n=1,600
NCT07400653 NOT YET RECRUITING
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
Pfizer n=999
NCT06993792 RECRUITING
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Eli Lilly and Company n=1,200
NCT07400107 NOT YET RECRUITING
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Novo Nordisk A/S n=1,000
NCT03811561 ACTIVE NOT RECRUITING
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
Novo Nordisk A/S n=1,500
NCT07394114 RECRUITING
A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=240
NCT07282613 NOT YET RECRUITING
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Novo Nordisk A/S n=80
NCT07379333 NOT YET RECRUITING
A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
Hanmi Pharmaceutical Company Limited n=118
NCT06221969 ACTIVE NOT RECRUITING
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk A/S n=1,000
NCT05803421 ACTIVE NOT RECRUITING
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company n=2,749
NCT06772168 RECRUITING
Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
CMG Pharmaceutical Co. Ltd n=240
NCT05099770 RECRUITING
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Prokidney n=685
NCT07271251 RECRUITING
A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes
Novo Nordisk A/S n=264
NCT07060456 RECRUITING
Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
Fujian Shengdi Pharmaceutical Co., Ltd. n=300
NCT06858878 ACTIVE NOT RECRUITING
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Amgen n=1,105
NCT06297603 ACTIVE NOT RECRUITING
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly and Company n=320
NCT07220759 RECRUITING
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Novo Nordisk A/S n=330
NCT07288749 NOT YET RECRUITING
Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction.
Tongji Hospital n=1,484
NCT06534411 ACTIVE NOT RECRUITING
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Novo Nordisk A/S n=1,023
NCT07219602 NOT YET RECRUITING
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NewAmsterdam Pharma n=300
NCT04670666 RECRUITING
Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus
EMS n=270
NCT06778967 ACTIVE NOT RECRUITING
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
Gan & Lee Pharmaceuticals. n=1,100
NCT06777238 ACTIVE NOT RECRUITING
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
Gan & Lee Pharmaceuticals. n=274
NCT07083154 RECRUITING
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School n=420
NCT06290349 ACTIVE NOT RECRUITING
Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Dong-A ST Co., Ltd. n=174
NCT06571591 ACTIVE NOT RECRUITING
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Celltrion n=582
NCT06972472 RECRUITING
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company n=600
NCT07064486 RECRUITING
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
BrightGene Bio-Medical Technology Co., Ltd. n=477
NCT05887271 RECRUITING
A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction
University of Leicester n=63
NCT07026968 ENROLLING BY INVITATION
A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
CSPC Ouyi Pharmaceutical Co., Ltd. n=815
NCT07193459 RECRUITING
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=360
NCT06254014 ACTIVE NOT RECRUITING
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients
Beijing Dongfang Biotech Co., Ltd. n=270
NCT06647745 RECRUITING
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
THPharm Corp. n=221
NCT07156500 NOT YET RECRUITING
A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone
Jiangsu Hansoh Pharmaceutical Co., Ltd. n=204
NCT07156539 NOT YET RECRUITING
A Phase 3 Study of HS-20094 in Patients With T2DM
Jiangsu Hansoh Pharmaceutical Co., Ltd. n=546
NCT07139535 NOT YET RECRUITING
A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
Guangdong Raynovent Biotech Co., Ltd n=350
NCT07139548 NOT YET RECRUITING
A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes
Guangdong Raynovent Biotech Co., Ltd n=600
NCT07059377 NOT YET RECRUITING
Semaglutide for Smoking Cessation in Patients With Diabetes
Ottawa Heart Institute Research Corporation n=100
NCT07093476 RECRUITING
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
Celltrion n=171
NCT06258148 ACTIVE NOT RECRUITING
A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. n=465
NCT06235086 ACTIVE NOT RECRUITING
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. n=632
NCT06649773 ACTIVE NOT RECRUITING
The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients
Jiangsu HengRui Medicine Co., Ltd. n=137
NCT06731075 NOT YET RECRUITING
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.
Oramed, Ltd. n=300
NCT05098470 ACTIVE NOT RECRUITING
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
University of Alabama at Birmingham n=100
NCT07082114 RECRUITING
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=800
NCT07033585 ACTIVE NOT RECRUITING
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair n=600
NCT07046273 NOT YET RECRUITING
Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes
Shandong New Time Pharmaceutical Co., LTD n=496
NCT06650007 ACTIVE NOT RECRUITING
the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone
Fujian Shengdi Pharmaceutical Co., Ltd. n=218
NCT06649344 ACTIVE NOT RECRUITING
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Fujian Shengdi Pharmaceutical Co., Ltd. n=884
NCT06260722 ACTIVE NOT RECRUITING
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Eli Lilly and Company n=1,250
NCT06672172 ACTIVE NOT RECRUITING
A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise
Shandong Suncadia Medicine Co., Ltd. n=284
NCT05929079 ACTIVE NOT RECRUITING
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company n=1,000
NCT06900075 NOT YET RECRUITING
Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. n=88
NCT06847178 NOT YET RECRUITING
Efficacy and Safety of LC-Z300-01 in Chinese With Type 2 Diabetes
Shanghai Changzheng Hospital n=60
NCT06246799 RECRUITING
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
The University of Texas Health Science Center at San Antonio n=256
NCT06192693 RECRUITING
Fecal Microbiota Transfer to Improve Diabetes Control Post-bariatric Surgery
Assistance Publique - Hôpitaux de Paris n=54
NCT06825182 RECRUITING
Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes
Nanjing First Hospital, Nanjing Medical University n=1,000
NCT06363747 ACTIVE NOT RECRUITING
The Medically Reproducing Bariatric Surgery (MRB) II Study
Durham VA Medical Center n=50
NCT06716203 RECRUITING
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
BrightGene Bio-Medical Technology Co., Ltd. n=207
NCT06716216 RECRUITING
A Study of BGM0504 in Participants with Type 2 Diabetes
BrightGene Bio-Medical Technology Co., Ltd. n=537
NCT06589765 RECRUITING
A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
Shandong Suncadia Medicine Co., Ltd. n=800
NCT05345327 RECRUITING
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
The George Institute n=994
NCT06616961 NOT YET RECRUITING
Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus
Popular Medical College Hospital n=480
NCT06559722 NOT YET RECRUITING
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
Tonghua Dongbao Pharmaceutical Co.,Ltd n=510
NCT06220773 RECRUITING
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
Boryung Pharmaceutical Co., Ltd n=276
NCT05466643 RECRUITING
A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus
Daewoong Pharmaceutical Co. LTD. n=240
NCT05505994 ACTIVE NOT RECRUITING
The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin
Daewoong Pharmaceutical Co. LTD. n=340
NCT06339086 NOT YET RECRUITING
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
Chengdu Brilliant Pharmaceutical Co., Ltd. n=478
NCT05886088 NOT YET RECRUITING
Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus
EMS n=597
NCT05211375 RECRUITING
Comparisons of Metabolic Effect of Sleeve Gastrectomy With Duodenojejunal Bypass and Sleeve Gastrectomy (MEDUSA): A Multicenter Randomized Controlled Trial
Seoul National University Bundang Hospital n=130
NCT02251431 COMPLETED
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
Baylor Research Institute n=57
NCT04596631 COMPLETED
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
Novo Nordisk A/S n=132
NCT04865770 COMPLETED
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
Novo Nordisk A/S n=106
NCT04251156 COMPLETED
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
Novo Nordisk A/S n=375
NCT05394519 COMPLETED
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Novo Nordisk A/S n=1,200
NCT06881264 COMPLETED
A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
Jiangsu HengRui Medicine Co., Ltd. n=401
NCT06065540 COMPLETED
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk A/S n=2,734
NCT06323174 COMPLETED
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Novo Nordisk A/S n=189
NCT06871761 COMPLETED
A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
Jiangsu HengRui Medicine Co., Ltd. n=393
NCT02354222 COMPLETED
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)
Tanabe Pharma Corporation n=154
NCT02354235 COMPLETED
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)
Tanabe Pharma Corporation n=138
NCT02924064 COMPLETED
Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus
Tanabe Pharma Corporation n=247
NCT02916706 COMPLETED
Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus
Tanabe Pharma Corporation n=254
NCT06415773 COMPLETED
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
HighTide Biopharma Pty Ltd n=367
NCT06350890 COMPLETED
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
HighTide Biopharma Pty Ltd n=408
NCT05834868 COMPLETED
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes
Tonghua Dongbao Pharmaceutical Co.,Ltd n=1,040
NCT06560333 WITHDRAWN
iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)
Eurofarma Laboratorios S.A.
NCT07057479 WITHDRAWN
Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin
Eurofarma Laboratorios S.A.
NCT04770532 COMPLETED
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
Novo Nordisk A/S n=526
NCT04560998 COMPLETED
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
Novo Nordisk A/S n=792
NCT05478252 COMPLETED
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
Novo Nordisk A/S n=388
NCT03914326 COMPLETED
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
Novo Nordisk A/S n=9,651
NCT04707469 COMPLETED
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
Novo Nordisk A/S n=1,606
NCT05352815 COMPLETED
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
Novo Nordisk A/S n=1,291
NCT04460885 COMPLETED
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
Novo Nordisk A/S n=984
NCT04880850 COMPLETED
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
Novo Nordisk A/S n=582
NCT04588259 COMPLETED
Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
Novo Nordisk A/S n=331
NCT05823948 COMPLETED
A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)
Novo Nordisk A/S n=51
NCT05013229 COMPLETED
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
Novo Nordisk A/S n=679
NCT06323161 COMPLETED
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
Novo Nordisk A/S n=274
NCT06353347 COMPLETED
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
HighTide Biopharma Pty Ltd n=551
NCT05514535 COMPLETED
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
Novo Nordisk A/S n=568
NCT06418880 COMPLETED
Automated Insulin Delivery for Inpatients With Dysglycemia
Emory University n=130
NCT04029480 COMPLETED
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
Merck Sharp & Dohme LLC n=166
NCT05649137 COMPLETED
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
Novo Nordisk A/S n=512
NCT05963022 COMPLETED
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
Eli Lilly and Company n=206
NCT06109311 COMPLETED
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Eli Lilly and Company n=546
NCT06192108 COMPLETED
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Eli Lilly and Company n=962
NCT03968224 COMPLETED
Effectiveness of Dapagliflozin for Weight Loss
Centro Medico Nacional Siglo XXI IMSS n=160
NCT05260021 COMPLETED
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
Eli Lilly and Company n=99
NCT06045221 COMPLETED
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Eli Lilly and Company n=1,698
NCT05872620 COMPLETED
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company n=1,613
NCT05680155 COMPLETED
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
Hangzhou Sciwind Biosciences Co., Ltd. n=211
NCT03508739 SUSPENDED
Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition
University of Pennsylvania n=25
NCT05814406 COMPLETED
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM
JW Pharmaceutical n=196
NCT05814393 COMPLETED
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus
JW Pharmaceutical n=200
NCT04760626 COMPLETED
A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
Novo Nordisk A/S n=1,085
NCT06269107 COMPLETED
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
Novo Nordisk A/S n=485
NCT04255433 COMPLETED
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company n=13,299
NCT05813912 COMPLETED
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
Novo Nordisk A/S n=148
NCT04429503 COMPLETED
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals n=660
NCT05662332 COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
Eli Lilly and Company n=795
NCT06739044 COMPLETED
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=494
NCT07076056 COMPLETED
Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
Daewon Pharmaceutical Co., Ltd. n=230
NCT06010004 COMPLETED
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
Eli Lilly and Company n=466
NCT06161844 COMPLETED
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=506
NCT07058545 COMPLETED
A Study of CJC-1134-PC Injection in Antidiabetic Treatment-naive Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. n=474
NCT07057271 COMPLETED
A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. n=464
NCT05259033 COMPLETED
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
Novo Nordisk A/S n=683
NCT04841096 COMPLETED
Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure
Laboratorios Silanes S.A. de C.V. n=162
NCT05275400 COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
Eli Lilly and Company n=986
NCT04090580 COMPLETED
Impact on Glycemic Variability in Newly Onset T2DM Patients Initiating Dapagliflozin Plus Metformin Versus Metformin Alone
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran n=88
NCT05362058 COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
Eli Lilly and Company n=928
NCT05680129 COMPLETED
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
Hangzhou Sciwind Biosciences Co., Ltd. n=623
NCT05205005 COMPLETED
Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes
VA Office of Research and Development n=24
NCT05462756 COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
Eli Lilly and Company n=730
NCT03170518 COMPLETED
A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
Janssen Research & Development, LLC n=171
NCT05971940 COMPLETED
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Eli Lilly and Company n=559
NCT05280496 COMPLETED
A Pragmatic Approach to Lower Diabetes Risk After Gestational Diabetes
Tufts Medical Center n=20
NCT05998837 COMPLETED
GLUcose Transport and REnalPROtection in Chronic Kidney Disease
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy n=34
NCT03819153 COMPLETED
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
Novo Nordisk A/S n=3,533
NCT04965935 COMPLETED
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
University Health Network, Toronto n=52
NCT04271189 COMPLETED
Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs
Azienda Ospedaliero-Universitaria di Parma n=108
NCT05702073 COMPLETED
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.
Jiangsu HengRui Medicine Co., Ltd. n=423
NCT05699408 COMPLETED
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs
Jiangsu HengRui Medicine Co., Ltd. n=513
NCT05504226 COMPLETED
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin
Handok Inc. n=214
NCT05504239 COMPLETED
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin
Handok Inc. n=235
NCT05566028 COMPLETED
The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes
Chong Kun Dang Pharmaceutical n=172
NCT04795531 COMPLETED
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
Novo Nordisk A/S n=588
NCT02794792 COMPLETED
A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
Astellas Pharma Europe B.V. n=268
NCT02452632 COMPLETED
A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin
Astellas Pharma Korea, Inc. n=143
NCT04017832 COMPLETED
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
Novo Nordisk A/S n=1,441
NCT05286853 WITHDRAWN
A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease
Prokidney
NCT04109547 COMPLETED
A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
Novo Nordisk A/S n=521
NCT05606913 COMPLETED
A Study of IBI362 in Participants With Type 2 Diabetes
Innovent Biologics (Suzhou) Co. Ltd. n=731
NCT05628311 COMPLETED
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
Innovent Biologics (Suzhou) Co. Ltd. n=319
NCT04807348 COMPLETED
Chiglitazar Added to Metformin for Type 2 Diabetes
Chipscreen Biosciences, Ltd. n=533
NCT06489457 COMPLETED
The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity
University Medical Centre Ljubljana n=25
NCT03199053 COMPLETED
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
AstraZeneca n=256
NCT04304261 COMPLETED
Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
Third Military Medical University n=100
NCT04809220 COMPLETED
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
Eli Lilly and Company n=591
NCT04657003 COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
Eli Lilly and Company n=938
NCT04460326 COMPLETED
Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
Boston Medical Center n=137
NCT04298229 COMPLETED
Efficacy and Safety of Dapagliflozin in Acute Heart Failure
Vanderbilt University Medical Center n=240
NCT06083675 WITHDRAWN
Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
Novo Nordisk A/S
NCT03429543 COMPLETED
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
Boehringer Ingelheim n=175
NCT04741074 TERMINATED
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
Geisinger Clinic n=15
NCT05816057 COMPLETED
A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus
Hangzhou Jiuyuan Gene Engineering Co. Ltd., n=476
NCT03164785 COMPLETED
Efficacy and Safety of Jinshuibao Capsule on Diabetic Kidney Disease
Second Xiangya Hospital of Central South University n=202
NCT04466618 COMPLETED
Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes
Adrian Vella n=23
NCT04233801 COMPLETED
A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
Boehringer Ingelheim n=219
NCT02512068 COMPLETED
A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease
Takeda n=107
NCT05369793 COMPLETED
Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy
Tanta University n=60
NCT04537923 COMPLETED
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
Eli Lilly and Company n=1,428
NCT03862716 COMPLETED
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira
Population Health Research Institute n=159
NCT04886388 COMPLETED
Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes
Better Therapeutics n=668
NCT05998525 COMPLETED
Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography
Hilda Elizabeth Macías Cervantes n=54
NCT05098327 WITHDRAWN
Pioglitazone and Insulin Resistance in ADT
State University of New York at Buffalo
NCT04504370 COMPLETED
Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
PegBio Co., Ltd. n=273
NCT04504396 COMPLETED
Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy
PegBio Co., Ltd. n=620
NCT04591626 COMPLETED
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
Eli Lilly and Company n=291
NCT05801627 COMPLETED
SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin
Shenzhen Salubris Pharmaceuticals Co., Ltd. n=408
NCT05782192 COMPLETED
SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Shenzhen Salubris Pharmaceuticals Co., Ltd. n=458
NCT03387787 COMPLETED
Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2
Insel Gruppe AG, University Hospital Bern n=15
NCT03174522 TERMINATED
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
Ixaka Ltd n=49
NCT03842267 COMPLETED
A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)
LG Chem n=315
NCT04605991 COMPLETED
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)
Eli Lilly and Company n=187
NCT03989232 COMPLETED
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
Novo Nordisk A/S n=961
NCT04754334 TERMINATED
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
Oramed, Ltd. n=346
NCT04606576 TERMINATED
Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
Oramed, Ltd. n=710
NCT04093752 COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
Eli Lilly and Company n=917
NCT03172494 COMPLETED
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
Novo Nordisk A/S n=720
NCT04564872 COMPLETED
HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
Sichuan Haisco Pharmaceutical Group Co., Ltd n=465
NCT04556851 COMPLETED
HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Sichuan Haisco Pharmaceutical Group Co., Ltd n=476
NCT03689374 COMPLETED
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
Novo Nordisk A/S n=2,274
NCT05444153 WITHDRAWN
Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
Novo Nordisk A/S
NCT03315143 TERMINATED
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
Lexicon Pharmaceuticals n=10,584
NCT03521934 TERMINATED
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
Lexicon Pharmaceuticals n=1,222
NCT05376969 COMPLETED
Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin
Daewoong Pharmaceutical Co. LTD. n=159
NCT05376930 COMPLETED
Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.
Daewoong Pharmaceutical Co. LTD. n=63
NCT04632862 COMPLETED
The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.
Daewoong Pharmaceutical Co. LTD. n=140
NCT04634500 COMPLETED
The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
Daewoong Pharmaceutical Co. LTD. n=200
NCT03076112 COMPLETED
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin
Seoul National University Bundang Hospital n=170
NCT04161430 COMPLETED
A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=766
NCT03610412 COMPLETED
Cinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated
Coordinación de Investigación en Salud, Mexico n=28
NCT02849080 COMPLETED
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
Novo Nordisk A/S n=504
NCT02863328 COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=822
NCT02692716 COMPLETED
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=3,183
NCT02906930 COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
Novo Nordisk A/S n=703
NCT02863419 COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=711
NCT02607865 COMPLETED
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=1,864
NCT03798054 COMPLETED
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
Sanofi n=878
NCT03798080 COMPLETED
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Sanofi n=426
NCT05451147 COMPLETED
A Comparative Study of the Effect of Ayurvedic Drugs and Metformin in the Management of Diabetes Mellitus (Type II)
A & U Tibbia College Karol Bagh n=48
NCT02963766 COMPLETED
A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
Eli Lilly and Company n=154
NCT03608358 TERMINATED
Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin
AstraZeneca n=41
NCT05360147 COMPLETED
Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus
Third Military Medical University n=30
NCT03761134 TERMINATED
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea
Sanofi n=377
NCT03760965 TERMINATED
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise
Sanofi n=276
NCT02855684 COMPLETED
Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy
Sanofi n=604
NCT03767543 COMPLETED
Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
Sanofi n=265
NCT03529123 COMPLETED
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
Sanofi n=247
NCT03861052 COMPLETED
A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes
Eli Lilly and Company n=636
NCT03371108 COMPLETED
Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Gan and Lee Pharmaceuticals, USA n=567
NCT04654390 COMPLETED
The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus
Daewoong Pharmaceutical Co. LTD. n=270
NCT03434119 TERMINATED
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
Sanofi n=241
NCT03211858 COMPLETED
Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine
Sanofi n=597
NCT02787551 COMPLETED
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Sanofi n=514
NCT02623998 COMPLETED
Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)
Population Health Research Institute n=102
NCT04356742 COMPLETED
Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Dong-A ST Co., Ltd. n=198
NCT05290506 COMPLETED
Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus
National University of Malaysia n=50
NCT02325466 COMPLETED
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
Icahn School of Medicine at Mount Sinai n=70
NCT02422446 TERMINATED
Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects
Brigham and Women's Hospital n=2
NCT02725593 COMPLETED
Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
AstraZeneca n=72
NCT03861039 COMPLETED
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
Eli Lilly and Company n=443
NCT03730662 COMPLETED
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
Eli Lilly and Company n=2,002
NCT03987919 COMPLETED
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
Eli Lilly and Company n=1,879
NCT03952143 COMPLETED
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
Eli Lilly and Company n=628
NCT04287179 WITHDRAWN
SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
Novo Nordisk A/S
NCT03882970 COMPLETED
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
Eli Lilly and Company n=1,444
NCT03353350 COMPLETED
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
Hanmi Pharmaceutical Company Limited n=406
NCT04039503 COMPLETED
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
Eli Lilly and Company n=475
NCT03078478 COMPLETED
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
Novo Nordisk A/S n=1,609
NCT03268005 COMPLETED
Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
Novo Nordisk A/S n=1,264
NCT03770728 TERMINATED
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
Sanofi n=312
NCT03713684 TERMINATED
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
Sanofi n=370
NCT04932213 COMPLETED
Effect of Tropicamide 0.5% vs Tropicamide 1% on Intraocular Pressure of Diabetic Patients
Semnan University of Medical Sciences n=98
NCT03684642 TERMINATED
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Sanofi n=908
NCT03954834 COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
Eli Lilly and Company n=478
NCT02643797 COMPLETED
Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings
Scripps Whittier Diabetes Institute n=602
NCT04510493 COMPLETED
Canakinumab in Patients With COVID-19 and Type 2 Diabetes
University Hospital, Basel, Switzerland n=116
NCT03141073 COMPLETED
Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects
Hua Medicine Limited n=767
NCT03173391 COMPLETED
Long-term Efficacy and Safety of HMS5552 in T2DM Subjects
Hua Medicine Limited n=463
NCT02586155 COMPLETED
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
Resverlogix Corp n=2,425
NCT04801199 COMPLETED
Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus
Cadila Pharnmaceuticals n=355
NCT03086330 COMPLETED
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=302
NCT02836873 COMPLETED
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
Theracos n=312
NCT04943692 SUSPENDED
Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes
Laboratorios Silanes S.A. de C.V. n=500
NCT04218734 COMPLETED
A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=214
NCT02715258 COMPLETED
Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes
Theracos n=210
NCT03242252 COMPLETED
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
Lexicon Pharmaceuticals n=787
NCT03242018 COMPLETED
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
Lexicon Pharmaceuticals n=277
NCT03386344 TERMINATED
Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Lexicon Pharmaceuticals n=376
NCT03115112 COMPLETED
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Theracos n=386
NCT02926937 COMPLETED
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
Lexicon Pharmaceuticals n=399
NCT04371978 TERMINATED
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
Rabin Medical Center n=64
NCT02769481 COMPLETED
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Theracos n=426
NCT02851745 COMPLETED
Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry
Heart Care Foundation n=188
NCT03338010 COMPLETED
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company n=536
NCT03332771 COMPLETED
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
Lexicon Pharmaceuticals n=954
NCT03066830 COMPLETED
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin
Lexicon Pharmaceuticals n=507
NCT02926950 COMPLETED
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
Lexicon Pharmaceuticals n=518
NCT03351478 COMPLETED
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
Lexicon Pharmaceuticals n=770
NCT03285594 COMPLETED
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
Lexicon Pharmaceuticals n=571
NCT03111238 TERMINATED
The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM
Ixaka Ltd n=3
NCT04857346 COMPLETED
Antimicrobial Photodynamic Therapy in Chronic Periodontitis and Diabetes Mellitus
King Saud University n=80
NCT02607306 COMPLETED
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
Novo Nordisk A/S n=819
NCT02911948 COMPLETED
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
Novo Nordisk A/S n=210
NCT04057261 WITHDRAWN
Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease
RWTH Aachen University
NCT03015220 COMPLETED
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
Novo Nordisk A/S n=458
NCT03061214 COMPLETED
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
Novo Nordisk A/S n=868
NCT02889510 COMPLETED
Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus
Lecube, Albert, M.D. n=76
NCT03018028 COMPLETED
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
Novo Nordisk A/S n=243
NCT03940183 COMPLETED
Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=254
NCT02964247 COMPLETED
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
Novo Nordisk A/S n=303
NCT03130426 COMPLETED
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
Population Health Research Institute n=161
NCT03711682 COMPLETED
Reducing Plasma Glucose Effect of Cinnamon in Type 2 Diabetic Patients in the Municipality of Comasagua
Universidad Dr. José Matías Delgado n=30
NCT02868177 COMPLETED
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes
Valbiotis n=66
NCT02908152 COMPLETED
Curcumin Supplement in Nonalcoholic Fatty Liver Patients
National Nutrition and Food Technology Institute n=50
NCT03343366 COMPLETED
Glycemic Control in T2DM Through Non-Surgical Periodontal Therapy
Dow University of Health Sciences n=150
NCT02773368 COMPLETED
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=420
NCT03349684 COMPLETED
Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients
Bayer n=287
NCT02597049 COMPLETED
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company n=424
NCT02752828 COMPLETED
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Sanofi n=521
NCT02752412 COMPLETED
Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
Sanofi n=513
NCT02749890 COMPLETED
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Sanofi n=321
NCT03495102 COMPLETED
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
Eli Lilly and Company n=1,842
NCT02561078 COMPLETED
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company n=420
NCT02536248 COMPLETED
Sitagliptin Therapy and Kinetics of Inflammatory Markers
Laval University n=20
NCT02320721 COMPLETED
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
Sanofi n=1,014
NCT03419624 TERMINATED
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
Universitätsklinikum Hamburg-Eppendorf n=13
NCT03214380 COMPLETED
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
Eli Lilly and Company n=933
NCT03175120 COMPLETED
A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
Novo Nordisk A/S n=453
NCT03021187 COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
Novo Nordisk A/S n=731
NCT03118336 COMPLETED
Impact of Empaglifozine on Cardiac Ectopic Fat
Assistance Publique Hopitaux De Marseille n=56
NCT02827708 COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
Novo Nordisk A/S n=324
NCT03136484 COMPLETED
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=788
NCT02501161 COMPLETED
A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=1,012
NCT02906917 COMPLETED
A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
Novo Nordisk A/S n=532
NCT03191396 COMPLETED
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
Novo Nordisk A/S n=577
NCT02648204 COMPLETED
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
Novo Nordisk A/S n=1,201
NCT03249259 COMPLETED
The Effect of Choline Alfoscerate on Improvement of Cognitive Function in Elderly Patients With Diabetes
Seoul National University Bundang Hospital n=36
NCT02547935 COMPLETED
A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
AstraZeneca n=459
NCT02683746 COMPLETED
Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
GlaxoSmithKline n=308
NCT04023344 COMPLETED
Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients
Geropharm n=210
NCT03707171 COMPLETED
Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus
Third Military Medical University n=30
NCT04012775 COMPLETED
Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients
Geropharm n=201
NCT02929901 COMPLETED
The Effects of Coffee Main Constituents (Caffeine and Chlorogenic Acid) Supplementation on Inflammatory, Metabolic Factors, Hepatic Steatosis and Fibrosis in None- Alcoholic Fatty Liver Patients With Type 2 Diabetes
National Nutrition and Food Technology Institute n=200
NCT02762578 COMPLETED
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=543
NCT03060980 TERMINATED
Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
Intarcia Therapeutics n=245
NCT02791490 COMPLETED
A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)
Merck Sharp & Dohme LLC n=458
NCT02738879 COMPLETED
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
Merck Sharp & Dohme LLC n=746
NCT02453555 COMPLETED
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
Boehringer Ingelheim n=275
NCT03015519 WITHDRAWN
A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus
GlaxoSmithKline
NCT02551874 COMPLETED
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
AstraZeneca n=650
NCT02630706 COMPLETED
A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)
Merck Sharp & Dohme LLC n=506
NCT02532855 COMPLETED
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
Merck Sharp & Dohme LLC n=614
NCT02084004 WITHDRAWN
Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment
Xijing Hospital
NCT02638805 COMPLETED
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
Intarcia Therapeutics n=136
NCT02413398 COMPLETED
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
AstraZeneca n=321
NCT02681094 COMPLETED
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
AstraZeneca n=905
NCT02648217 COMPLETED
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan
Novo Nordisk A/S n=263
NCT02489968 COMPLETED
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Boehringer Ingelheim n=880
NCT02505334 COMPLETED
A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.
Novo Nordisk A/S n=635
NCT02564211 COMPLETED
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
Merck Sharp & Dohme LLC n=77
NCT02577003 COMPLETED
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
Merck Sharp & Dohme LLC n=143
NCT02739984 COMPLETED
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
Amgen n=424
NCT02577016 COMPLETED
Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)
Merck Sharp & Dohme LLC n=141
NCT02315495 COMPLETED
Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes
Zilin Sun n=22
NCT02827903 COMPLETED
Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia
Jeil Pharmaceutical Co., Ltd. n=237
NCT03437902 COMPLETED
Impact of Rutin and Vitamin C Combination on Oxidative Stress, Insulin Sensitivity and Lipid Profile in Type 2 Diabetic Patients
Ain Shams University n=53
NCT02420262 COMPLETED
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=506
NCT02831361 COMPLETED
Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)
LG Life Sciences n=290
NCT02294474 COMPLETED
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
Sanofi n=505
NCT02786823 COMPLETED
Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes
All India Institute of Medical Sciences, Bhubaneswar n=80
NCT02216552 COMPLETED
Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents
University of Manitoba n=10
NCT03125694 COMPLETED
Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea
Tehran University of Medical Sciences n=250
NCT02585674 COMPLETED
Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo
Sanofi n=151
NCT02401243 COMPLETED
Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients
Sanofi n=253
NCT02106364 WITHDRAWN
A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
NCT02229240 WITHDRAWN
Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
GlaxoSmithKline
NCT01984606 WITHDRAWN
Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
Boehringer Ingelheim
Data: ClinicalTrials.gov